EGFR and non-small cell lung carcinoma: Despite the favourable clinical responses ascribed to molecular targeted therapy (such as anti‐EGFR tyrosine kinase inhibitors [TKIs] or monoclonal antibodies), clinical benefit is largely restricted to NSCLC patients with classical activating EGFR mutations,10, 11 namely, exon 19 and exon 21 L858R mutations.